{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:06:09Z","timestamp":1771484769304,"version":"3.50.1"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Tennessee at Chattanooga"},{"name":"Solvay Pharmaceuticals (Marietta, GA)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacology Biochemistry and Behavior"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.pbb.2013.01.006","type":"journal-article","created":{"date-parts":[[2013,1,17]],"date-time":"2013-01-17T05:18:42Z","timestamp":1358399922000},"page":"119-124","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Ritualistic Chewing Behavior induced by mCPP in the rat is an animal model of Obsessive Compulsive Disorder"],"prefix":"10.1016","volume":"104","author":[{"given":"Deborah S.","family":"Kreiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine F.","family":"Coffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas R.","family":"Fiacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jason C.","family":"Granger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette M.","family":"Helton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer C.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid V.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rishi S.","family":"Mistry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammie M.","family":"Mizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lolita V.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay A.","family":"Vacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart S.","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin A.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pbb.2013.01.006_bb0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.neubiorev.2011.04.006","article-title":"Animal models of obsessive\u2013compulsive disorder: exploring pharmacology and neural substrates","volume":"46","author":"Albelda","year":"2012","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1016\/j.pbb.2013.01.006_bb0010","series-title":"Diagnostic and statistical manual of mental disorders, fourth edition text revision (DSM-IV-TR)","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.pbb.2013.01.006_bb0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/15622970802465807","article-title":"World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive\u2013compulsive and post-traumatic stress disorders \u2014 first revision","volume":"9","author":"Bandelow","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0015","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.02.022","article-title":"Behavioral effects of four antidepressants on an ischemic rat model of emotional disturbances","volume":"201","author":"Bantsiele","year":"2009","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.pbb.2013.01.006_bb0025","series-title":"Psychopharmacology: the fourth generation","first-page":"1287","article-title":"Neuroimaging studies of human anxiety disorders","author":"Baxter","year":"1995"},{"key":"10.1016\/j.pbb.2013.01.006_bb0030","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/syn.890150310","article-title":"Chronic treatment with fluvoxamine increases extracellular serotonin in frontal cortex but not in raphe nuclei","volume":"15","author":"Bel","year":"1993","journal-title":"Synapse"},{"key":"10.1016\/j.pbb.2013.01.006_bb0035","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1001\/archpsyc.1990.01810210048007","article-title":"Local cerebral glucose metabolic rates in obsessive\u2013compulsive disorder: patients treated with clomipramine","volume":"47","author":"Benkelfat","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0040","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002130050568","article-title":"mCPP-induced anxiety in the light-dark box in rats\u2014a new method for screening anxiolytic activity","volume":"136","author":"Bilkei-Gorzo","year":"1998","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0925-4927(00)00050-0","article-title":"A voxel-based investigation of regional cerebral blood flow abnormalities in obsessive\u2013compulsive disorder using single photon emission computed tomography (SPECT)","volume":"99","author":"Busatto","year":"2000","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pbb.2013.01.006_bb0050","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jpsychires.2005.04.010","article-title":"Obsessive\u2013compulsive disorder: a 3-year prospective follow-up study of patients treated with serotonin reuptake inhibitors OCD follow-up study","volume":"40","author":"Catapano","year":"2006","journal-title":"Psychiatr Res"},{"key":"10.1016\/j.pbb.2013.01.006_bb0055","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1001\/archpsyc.1991.01810320054008","article-title":"Clomipramine in the treatment of patients with obsessive\u2013compulsive disorder","volume":"48","author":"Clomipramine Collaborative Group","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0060","doi-asserted-by":"crossref","first-page":"5170","DOI":"10.1523\/JNEUROSCI.20-13-05170.2000","article-title":"Nigrostriatal lesions alter oral dyskinesia and c-Fos expression induced by the serotonin agonist 1-(m-chlorophenyl)piperazine in adult rats","volume":"20","author":"De Deurwaerdere","year":"2000","journal-title":"J Neurosci"},{"key":"10.1016\/j.pbb.2013.01.006_bb0065","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0306-4522(95)00548-X","article-title":"A role for the subthalamic nucleus in 5-HT2C-induced oral dyskinesia","volume":"72","author":"Eberle-Wang","year":"1996","journal-title":"Neuroscience"},{"key":"10.1016\/j.pbb.2013.01.006_bb0070","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0893-133X(00)00178-0","article-title":"Low versus standard dose mCPP challenge in obsessive\u2013compulsive patients","volume":"24","author":"Erzegovesi","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0075","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1176\/appi.ajp.162.1.151","article-title":"Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive\u2013compulsive disorder","volume":"162","author":"Foa","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb9000","first-page":"301","article-title":"Fluvoxamine versus clomipramine in the treatment of obsessive compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison","volume":"55","author":"Freeman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0080","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/0091-3057(92)90383-Q","article-title":"Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats","volume":"41","author":"Gong","year":"1992","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.01.006_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1001\/archpsyc.1989.01810010038006","article-title":"Efficacy of fluvoxamine in obsessive\u2013compulsive disorder: a double-blind comparison with placebo","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0085","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/archpsyc.1990.01810180077011","article-title":"Specificity of serotonin reuptake inhibitors in the treatment of obsessive\u2013compulsive disorder. Comparison of fluvoxamine and desipramine","volume":"47","author":"Goodman","year":"1990","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0095","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1124\/jpet.106.113357","article-title":"5-Hydroxytryptamine2C receptor contribution to m-chlorophenylpiperazine and N-methyl-beta-carboline-3-carboxamide-induced anxiety-like behavior and limbic brain activation","volume":"320","author":"Hackler","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.01.006_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/archpsyc.57.1.76","article-title":"Multicenter double-blind comparison of sertraline and desipramine for concurrent obsessive\u2013compulsive and major depressive disorders","volume":"57","author":"Hoehn-Saric","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0165-1781(91)90113-4","article-title":"Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive\u2013compulsive disorder","volume":"36","author":"Hollander","year":"1991","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pbb.2013.01.006_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.1992.01820010021003","article-title":"Serotonergic function in obsessive\u2013compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers","volume":"49","author":"Hollander","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0115","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/15622970309167908","article-title":"A double-blind, placebo-controlled trial of clonazepam in obsessive\u2013compulsive disorder","volume":"4","author":"Hollander","year":"2003","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0120","doi-asserted-by":"crossref","first-page":"640","DOI":"10.4088\/JCP.v64n0604","article-title":"A double-blind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive\u2013compulsive disorder","volume":"64","author":"Hollander","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0125","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/0028-3908(89)90143-3","article-title":"Behavioural profiles of putative 5-hydroxytryptamine receptor agonists and antagonists in developing rats","volume":"28","author":"Jackson","year":"1989","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0130","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1176\/ajp.147.9.1209","article-title":"A controlled trial of fluvoxamine in obsessive\u2013compulsive disorder: implications for a serotonergic theory","volume":"147","author":"Jenike","year":"1990","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.pnpbp.2005.11.006","article-title":"Current animal models of obsessive compulsive disorder: a critical review","volume":"30","author":"Joel","year":"2006","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/01.fbp.0000132925.81402.0a","article-title":"Compulsive lever-pressing in rats is attenuated by the serotonin re-uptake inhibitors paroxetine and fluvoxamine but not by the tricyclic antidepressant desipramine or the anxiolytic diazepam","volume":"15","author":"Joel","year":"2004","journal-title":"Behav Pharmacol"},{"key":"10.1016\/j.pbb.2013.01.006_bb0145","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/archpsyc.1988.01800360042006","article-title":"The epidemiology of obsessive\u2013compulsive disorder in five U.S. communities","volume":"45","author":"Karno","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0150","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/BF02245708","article-title":"Effects of housing, restraint and chronic treatments with mCPP and sertraline on behavioural responses to mCPP","volume":"113","author":"Kennedy","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0155","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1476-5381.1988.tb11508.x","article-title":"Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors","volume":"94","author":"Kennett","year":"1988","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pbb.2013.01.006_bb0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/0014-2999(89)90252-5","article-title":"Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists","volume":"164","author":"Kennett","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.01.006_bb0160","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/0028-3908(94)90133-3","article-title":"Effect of chronic administration of selective 5-hydroxytryptamine and noradrenaline uptake inhibitors on a putative index of 5-HT2C\/2B receptor function","volume":"33","author":"Kennett","year":"1994","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0170","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/00004714-199604000-00004","article-title":"Fluvoxamine versus clomipramine for obsessive\u2013compulsive disorder: a double-blind comparison","volume":"16","author":"Koran","year":"1996","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.pbb.2013.01.006_bb0175","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.psc.2006.02.007","article-title":"Animal models of obsessive\u2013compulsive disorder: rationale to understanding psychobiology and pharmacology","volume":"29","author":"Korff","year":"2006","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.pbb.2013.01.006_bb0180","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0022-3565(25)10650-2","article-title":"Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo","volume":"274","author":"Kreiss","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.01.006_bb0185","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0925-4927(03)00061-1","article-title":"Elevated thalamic and prefrontal regional cerebral blood flow in obsessive\u2013compulsive disorder: a SPECT study","volume":"123","author":"Lacerda","year":"2003","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.pbb.2013.01.006_bb0190","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0091-3057(93)90375-4","article-title":"Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agonists in the rat","volume":"46","author":"Liminga","year":"1993","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.01.006_bb0195","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0022-3565(25)23232-3","article-title":"Effect of 1-(m-chlorophenyl)piperazine and 1-(m-trifluoromethylphenyl)piperazine on locomotor activity","volume":"249","author":"Lucki","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pbb.2013.01.006_bb0200","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/BF01244819","article-title":"Effects of sertraline and citalopram given repeatedly on the responsiveness of 5-HT receptor subpopulations","volume":"88","author":"Maj","year":"1992","journal-title":"J Neural Transm Gen Sect"},{"key":"10.1016\/j.pbb.2013.01.006_bb0205","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive\u2013compulsive disorder. A multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.pbb.2013.01.006_bb0210","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1742-1241.2007.01356.x","article-title":"Issues in the pharmacological treatment of obsessive\u2013compulsive disorder","volume":"61","author":"Math","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.pbb.2013.01.006_bb0215","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/S0193-953X(18)30148-5","article-title":"The psychopharmacology of obsessive compulsive disorder. Implications for treatment and pathogenesis","volume":"16","author":"McDougle","year":"1993","journal-title":"Psychiatr Clin North Am"},{"key":"10.1016\/j.pbb.2013.01.006_bb0220","series-title":"Guide for care and use of laboratory animals","author":"National Research Council","year":"1996"},{"key":"10.1016\/j.pbb.2013.01.006_bb0225","series-title":"Guidelines for the care and use of mammals in neuroscience and behavioral research","author":"National Research Council and Institute for Laboratory Research","year":"2003"},{"key":"10.1016\/j.pbb.2013.01.006_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF02244874","article-title":"Dose-dependent differences in the development of reserpine-induced oral dyskinesia in rats","volume":"116","author":"Neisewander","year":"1994","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0235","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1176\/ajp.145.12.1521","article-title":"Return of symptoms after discontinuation of clomipramine in patients with obsessive\u2013compulsive disorder","volume":"145","author":"Pato","year":"1988","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0240","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1192\/bjp.166.4.424","article-title":"Efficacy of drug treatment in obsessive\u2013compulsive disorder. A meta-analytic review","volume":"166","author":"Piccinelli","year":"1995","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0245","doi-asserted-by":"crossref","first-page":"101","DOI":"10.4088\/JCP.v60n0206","article-title":"A review of the efficacy of selective serotonin reuptake inhibitors in obsessive\u2013compulsive disorder","volume":"60","author":"Pigott","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0250","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/0006-3223(91)90264-M","article-title":"Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive\u2013compulsive disorder","volume":"29","author":"Pigott","year":"1991","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0255","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/BF02245863","article-title":"Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats","volume":"119","author":"Plech","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0260","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/archpsyc.1994.03950010062008","article-title":"Regional cerebral blood flow measured during symptom provocation in obsessive\u2013compulsive disorder using oxygen 15-labeled carbon dioxide and positron emission tomography","volume":"51","author":"Rauch","year":"1994","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0265","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","article-title":"Fluoxamine for children and adolescents with obsessive\u2013compulsive disorder: a randomized, controlled, multicenter trial","volume":"40","author":"Riddle","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0270","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/mp.2008.94","article-title":"The epidemiology of obsessive\u2013compulsive disorder in the National Comorbidity Survey Replication","volume":"15","author":"Ruscio","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0275","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0304-3940(94)90635-1","article-title":"Increase in extracellular serotonin produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine","volume":"171","author":"Rutter","year":"1994","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pbb.2013.01.006_bb0280","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jad.2004.03.011","article-title":"Do antipsychotics ameliorate or exacerbate Obsessive Compulsive Disorder symptoms? A systematic review","volume":"82","author":"Sareen","year":"2004","journal-title":"J Affect Disord"},{"key":"10.1016\/j.pbb.2013.01.006_bb0285","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0193-953X(05)70181-7","article-title":"Functional neuroimaging and the neuroanatomy of obsessive\u2013compulsive disorder","volume":"23","author":"Saxena","year":"2000","journal-title":"Psychiatr Clin N Am"},{"key":"10.1016\/j.pbb.2013.01.006_bb0290","doi-asserted-by":"crossref","first-page":"269","DOI":"10.4088\/JCP.v67n0214","article-title":"Response versus remission in obsessive\u2013compulsive disorder","volume":"67","author":"Simpson","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0295","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0006-3223(02)01574-3","article-title":"Induction of c-Fos expression in specific areas of the fear circuitry in rat forebrain by anxiogenic drugs","volume":"53","author":"Singewald","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0300","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.neuroimage.2006.01.046","article-title":"Functional magnetic resonance imaging and c-Fos mapping in rats following an anorectic dose of m-chlorophenylpiperazine","volume":"31","author":"Stark","year":"2006","journal-title":"Neuroimage"},{"key":"10.1016\/j.pbb.2013.01.006_bb0305","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0014-2999(89)90608-0","article-title":"Induction of purposeless chewing behaviour in rats by 5-HT agonist drugs","volume":"162","author":"Stewart","year":"1989","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pbb.2013.01.006_bb9005","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.biopsych.2005.02.020","article-title":"Reinforced spatial alternation as an animal model of obsessive-compulsive disorder (OCD): investigation of 5-HT2C and 5-HT1D receptor involvement in OCD pathophysiology","volume":"57","author":"Tsaltas","year":"2005","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0310","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.pbb.2004.04.009","article-title":"Age differences in an animal model of obsessive\u2013compulsive disorder: participation of dopamine: dopamine in an animal model of OCD","volume":"78","author":"Ulloa","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.01.006_bb0315","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0278-5846(98)00024-4","article-title":"A discriminative stimulus produced by 1-(3-chlorophenyl)-piperazine (mCPP) as a putative animal model of anxiety","volume":"22","author":"Wallis","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0320","first-page":"5","article-title":"The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group","volume":"55","author":"Weissman","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0325","series-title":"Program No. 741.1. 2006 Neuroscience Meeting Planner","article-title":"mCPP-induced ritualistic chewing behaviors in rats as related to a putative animal model of Obsessive Compulsive Disorder","author":"Winkler","year":"2006"},{"key":"10.1016\/j.pbb.2013.01.006_bb0330","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF02244910","article-title":"Selective serotonin re-uptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive compulsive disorder","volume":"112","author":"Woods","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pbb.2013.01.006_bb0335","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.pbb.2004.05.003","article-title":"Chronic treatment with fluvoxamine desensitizes 5-HT2C receptor-mediated hypolocomotion in rats","volume":"78","author":"Yamauchi","year":"2004","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.pbb.2013.01.006_bb0340","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0006-3223(87)90199-5","article-title":"Obsessive\u2013compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology","volume":"22","author":"Zohar","year":"1987","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.pbb.2013.01.006_bb0345","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1001\/archpsyc.1988.01800260081011","article-title":"Serotonergic responsivity in obsessive\u2013compulsive disorder. Effects of chronic clomipramine treatment","volume":"45","author":"Zohar","year":"1988","journal-title":"Arch Gen Psychiatry"}],"container-title":["Pharmacology Biochemistry and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713000105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091305713000105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T17:23:44Z","timestamp":1745947424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091305713000105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":71,"alternative-id":["S0091305713000105"],"URL":"https:\/\/doi.org\/10.1016\/j.pbb.2013.01.006","relation":{},"ISSN":["0091-3057"],"issn-type":[{"value":"0091-3057","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}